Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Blood Rev. 2018 Mar;32(2):96-105. doi: 10.1016/j.blre.2017.09.002. Epub 2017 Sep 18.
Acute erythroleukemia is a rare form of acute myeloid leukemia recognized by its distinct phenotypic attribute of erythroblastic proliferation. After a century of its descriptive history, many diagnostic, prognostic, and therapeutic implications relating to this unique leukemia subset remain uncertain. The rarity of the disease and the simultaneous involvement of its associated myeloid compartment have complicated in vitro studies of human erythroleukemia cell lines. Although murine and cell line erythroleukemia models have provided valuable insights into pathophysiology, translation of these concepts into treatment are not forthcoming. Integration of knowledge gained through a careful study of these models with more recent data emerging from molecular characterization will help elucidate key mechanistic pathways and provide a much needed framework that accounts for erythroid lineage-specific attributes. In this article, we discuss the evolving diagnostic concept of erythroleukemia, translational aspects of its pathophysiology, and promising therapeutic targets through an appraisal of the current literature.
急性红白血病是一种罕见的急性髓系白血病，其特征性表型特征为红细胞增生。在其描述性历史的一个世纪后，与这种独特的白血病亚型相关的许多诊断、预后和治疗意义仍然不确定。这种疾病的罕见性以及其相关髓系成分的同时参与，使得人类红白血病细胞系的体外研究变得复杂。尽管鼠类和细胞系红白血病模型为病理生理学提供了有价值的见解，但这些概念向治疗的转化尚未实现。通过仔细研究这些模型获得的知识与最近从分子特征中出现的新数据的整合，将有助于阐明关键的机制途径，并提供一个急需的框架，该框架考虑到红细胞谱系特异性属性。在本文中，我们通过评估当前文献，讨论了急性红白血病不断发展的诊断概念、其病理生理学的转化方面以及有前途的治疗靶点。
